Related Experiment Video
Updated: May 8, 2026
09:55
Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
Published on: October 4, 2024
Submitting compelling case reports for drug therapy in veterinary patients
1North Carolina State University, College of Veterinary Medicine, Raleigh, North Carolina.
International Journal of Pharmaceutical Compounding
|August 24, 2013
Summary
Veterinarians and pharmacists can create valuable case reports from clinical experience when scientific data is lacking. Compounding pharmacists can share their expertise to advance veterinary medical care.
Area of Science:
- Veterinary Medicine
- Pharmaceutical Sciences
- Clinical Case Reporting
Background:
- Peer-reviewed scientific information is often unavailable for veterinary treatment planning.
- Veterinarians and pharmacists rely on clinical experience and colleague consultations.
- Compounding pharmacists possess extensive clinical experience valuable for education.
Purpose of the Study:
- To outline a method for compounding pharmacists to generate useful case reports.
- To leverage the clinical experience of compounding pharmacists for veterinary medical advancement.
- To provide guidelines for preparing case reports that meet editorial standards.
Main Methods:
- Proactively collect clinical data from veterinary patient cases.
- Carefully select appropriate cases for presentation.
- Collate case details into a compelling narrative with a clear message.
Main Results:
- Case reports and case series can be prepared using specific guidelines.
- This process allows for the contribution of valuable clinical experience to veterinary literature.
- Prepared case reports can potentially survive editorial review.
Conclusions:
- Compounding pharmacists can significantly contribute to veterinary medical knowledge through case reporting.
- Structured case report preparation enhances the educational value of clinical experience.
- This method aids in advancing veterinary medical care by disseminating practical insights.
Related Concept Videos
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:23Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...